Literature DB >> 21498633

A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.

Jason M Shohet1, Rajib Ghosh, Cristian Coarfa, Andrew Ludwig, Ashley L Benham, Zaowen Chen, Danielle M Patterson, Eveline Barbieri, Pieter Mestdagh, Denae N Sikorski, Aleksandar Milosavljevic, Eugene S Kim, Preethi H Gunaratne.   

Abstract

MYCN is a major driver of neuroblastoma tumorigenesis and MYCN amplification is the worst prognostic indicator of aggressive NB. To identify potentially therapeutic tumor suppressor microRNAs for aggressive NB, we utilized a conditional MYCN system to simulate MYCN-amplified and nonamplified tumor types and performed a genome-wide search for MYCN target microRNA promoters differentially repressed under high MYCN conditions. We identified 20 gene promoters hosting 30 microRNAs that were directly bound and differentially regulated by MYCN. Eleven of these genes showed significant clinical correlations for neuroblastoma with 4 genes linked with better survival and 7 genes linked with poor survival. Surprisingly, expression analysis of host genes and microRNAs demonstrated that 8 of 11 pairs were repressed by high levels of MYCN regardless of the clinical correlation of the host gene. We therefore predicted these intronic microRNAs would be tumor suppressors. In fact, detailed gain of function studies for two miRs, miR-591 and miR-558, confirmed potent tumor suppressive effects for miR-591 in orthotopic neuroblastoma xenografts. However, miR-558 markedly increased colony formation, proliferation, and tumor growth in vivo. Our data reveal host-gene independent functions of MYCN-target microRNAs and demonstrate that MYCN represses both tumor suppressive and proproliferative microRNAs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498633     DOI: 10.1158/0008-5472.CAN-10-4391

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

2.  G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation.

Authors:  Saurabh Agarwal; Anna Lakoma; Zaowen Chen; John Hicks; Leonid S Metelitsa; Eugene S Kim; Jason M Shohet
Journal:  Cancer Res       Date:  2015-04-23       Impact factor: 12.701

Review 3.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

4.  Redefining functional MYCN gene signatures in neuroblastoma.

Authors:  Jason Matthew Shohet
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-08       Impact factor: 11.205

5.  Myocardial microRNAs associated with reverse remodeling in human heart failure.

Authors:  Carmen C Sucharov; David P Kao; J David Port; Anis Karimpour-Fard; Robert A Quaife; Wayne Minobe; Karin Nunley; Brian D Lowes; Edward M Gilbert; Michael R Bristow
Journal:  JCI Insight       Date:  2017-01-26

6.  Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines.

Authors:  JiHoon Kang; EunGi Kim; Wanyeon Kim; Ki Moon Seong; HyeSook Youn; Jung Woo Kim; Joon Kim; BuHyun Youn
Journal:  J Biol Chem       Date:  2013-07-31       Impact factor: 5.157

Review 7.  Neuroblastoma: molecular pathogenesis and therapy.

Authors:  Chrystal U Louis; Jason M Shohet
Journal:  Annu Rev Med       Date:  2014-10-27       Impact factor: 13.739

8.  Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma.

Authors:  Eric A Hungate; Mark A Applebaum; Andrew D Skol; Zalman Vaksman; Maura Diamond; Lee McDaniel; Samuel L Volchenboum; Barbara E Stranger; John M Maris; Sharon J Diskin; Kenan Onel; Susan L Cohn
Journal:  J Natl Cancer Inst       Date:  2017-10-01       Impact factor: 13.506

9.  LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

Authors:  Jan J Molenaar; Raquel Domingo-Fernández; Marli E Ebus; Sven Lindner; Jan Koster; Ksenija Drabek; Pieter Mestdagh; Peter van Sluis; Linda J Valentijn; Johan van Nes; Marloes Broekmans; Franciska Haneveld; Richard Volckmann; Isabella Bray; Lukas Heukamp; Annika Sprüssel; Theresa Thor; Kristina Kieckbusch; Ludger Klein-Hitpass; Matthias Fischer; Jo Vandesompele; Alexander Schramm; Max M van Noesel; Luigi Varesio; Frank Speleman; Angelika Eggert; Raymond L Stallings; Huib N Caron; Rogier Versteeg; Johannes H Schulte
Journal:  Nat Genet       Date:  2012-10-07       Impact factor: 38.330

10.  G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic.

Authors:  Danielle M Hsu; Saurabh Agarwal; Ashley Benham; Cristian Coarfa; Denae N Trahan; Zaowen Chen; Paris N Stowers; Amy N Courtney; Anna Lakoma; Eveline Barbieri; Leonid S Metelitsa; Preethi Gunaratne; Eugene S Kim; Jason M Shohet
Journal:  Cancer Res       Date:  2013-05-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.